• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Gynecologic Cancers: ASCO2O Virtual Scientific Program Highlights for the Advanced Practitioner
【24h】

Gynecologic Cancers: ASCO2O Virtual Scientific Program Highlights for the Advanced Practitioner

机译：妇科癌症：ASCO2O虚拟科学计划为先进的医生突出显示

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Two phase III trials provide support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the ASCO20 Virtual Scientific Program, found cytoreductive surgery improved outcomes in selected patients. DESKTOP III is the first randomized phase III trial to demonstrate an improvement in survival with secondary surgery for recurrent ovarian cancer. In this study, secondary surgery prior to second-line chemotherapy extended median overall survival from 46 months with second-line chemotherapy and no surgery to 53.7 months (P = .02).1 However, the benefit of secondary surgery was observed only in cases where a complete resection was achieved.
机译：两项III期临床试验为复发性卵巢癌患者的二次细胞减灭术提供了支持，但需要注意的是，患者的选择是关键，手术应在最佳位置进行。在ASCO20虚拟科学项目期间，桌面III和SOC1试验的结果均显示，细胞减灭术改善了选定患者的预后。DESKTOP III是第一个证明复发性卵巢癌二次手术后生存率改善的随机III期试验。在这项研究中，二线化疗前的二次手术将中位总生存期从接受二线化疗的46个月和未经手术的53.7个月延长到53.7个月（P=.02）。1然而，只有在完全切除的情况下，才观察到二次手术的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号